

References

L-164

1. National Comprehensive Cancer Network: Practice Guidelines in Oncology 2.2018. Non-Small Cell Lung Cancer.
2. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. *N Eng J Med*. 2005;353:133-44.
3. Erlotinib (Tarceva®) prescribing Information. San Francisco, CA 94080-4990: Genentech Oncology. Revised April 2010.
4. Gefitinib (Iressa®) prescribing Information. Wilmington, DE 19850: Astra Zeneca Pharmaceuticals.
5. Afatinib (Gilotrif®) prescribing information. Ridgefield, CT 06877: Boehringer Ingelheim International GmbH.
6. Lindeman N, Cagle P, Ladanyi M, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Archives Of Pathology & Laboratory Medicine* June 2013;137(6):828-860.
7. FDA. Table of valid genomic biomarkers in the context of approved drug labels.
8. Leigh NB, Rekhtman N, William A. Biermann WA, et al. Molecular Testing for Selection of Patients with Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. *J Clin Oncol*. 2014;32(32):3673-79.
9. Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. *Journal of Hematology & Oncology*. 2016;9(34):1-7.
10. Osimertinib (Tagrisso®) prescribing information. Wilmington, DE 19850: AstraZenica Pharmaceuticals.